Details The technical summary data is suggesting a short of APLS if it tests 36.47 with a downside target of 29.74. We should ...

Shares of NASDAQ APLS opened at $29.98 on Thursday ... the director now owns 100,000 shares of the company’s stock, valued at ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eighteen analysts that are currently covering the firm, MarketBeat ...

Check the time stamp on this data. Updated AI-Generated Signals for Apellis Pharmaceuticals Inc. (APLS) available here: APLS.

The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock ...

The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024.

Commercial-stage biotech stocks typically trade at mid-single-digit multiples of their annual sales, regardless of how high those sales run. If total pegcetacoplan sales reach their expected peak ...

RBC Capital Mkts has recently initiated Apellis Pharmaceuticals Inc (APLS) stock to Sector Perform rating, as announced on October 25, 2024, according to Finviz. Earlier, on October 16, 2024, William ...

On Monday, Citi reaffirmed its Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) stock with a steady price target of $63.00. The endorsement follows the company's presentation at the American ...